SAH-STRAIN: Detection of Myocardial Dysfunction in Non-severe Subarachnoid Hemorrhage (WFNS 1-2) Using Speckle-tracking Echocardiography (STRAIN)

Sponsor

University Hospital, Bordeaux (Other)

Overall Status

Completed

CT.gov ID

NCT03761654

Collaborator

(none)

117

Enrollment

Location

Actual Duration (Months)

4.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Subarachnoid hemorrhage (SAH) can cause transient myocardial dysfunction. Recently, it have been reported that myocardial dysfunctions that occur in SAH are associated with poor outcomes. It therefore appears essential to detect theses dysfunctions with the higher sensitivity as possible. Strain measurement using speckle-tracking echocardiography may detect myocardial dysfunction with great sensitivity. The main objective of this study is to assess the prevalence of myocardial dysfunction in "non-severe" SAH (defined by a WFNS grade 1 or 2), using speckle-tracking echocardiography. This study also aims to analyse Strain measurement with classical echocardiography and serum markers (troponin, BNP) of cardiac dysfunction.

Condition or Disease	Intervention/Treatment	Phase
Subarachnoid Hemorrhage (SAH) Left Ventricular Dysfunction Stress Cardiomyopathy	Diagnostic Test: Global Longitudinal Strain measure

Detailed Description

Cardiac complication, occurring in the early phase of SAH has been well described. It seems that the pathophysiological mechanism involves vegetative hyperactivity due to the acute cerebral injury. It has been shown that stress cardiomyopathy is associated with delayed cerebral ischemia (DCI) and poor outcomes. Manifestations of stress cardiomyopathy are changes in electrocardiogram, release of cardiac biomarkers such as troponin and BNP, and echography evidence of impaired left ventricle ejection fraction with the use of Simpson technique and regional wall motion abnormalities. These two techniques bear intra-observer variability. A new method is available to assess left ventricular contractility at the bedside. Two-dimensional speckle-tracking images with echocardiography allows one to track a natural myocardial marker within the myocardium by standard transthoracic echocardiography. It provides unique insights into myocardial function such as tissue deformations and strain rate, which is the rate of deformation. This method is more sensitive than classical echographic left ventricular ejection fraction evaluation and bears very low interobserver variability. The Global Longitudinal Strain (GLS) is the most studied parameter.

Early detection of cardiac dysfunction in SAH followed by appropriate monitoring and management may improve outcome in SAH. This is a prospective, observational and mono-center study.

Patients with "non-severe" SAH will benefit from an echocardiography where Left Ventricular Ejection Fraction (LVEF) and GLS will be assessed on day 1, 3 and 7 following the acute injury.

Study Design

Study Type:

Observational

Actual Enrollment :

117 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Detection of Myocardial Dysfunction in Non-severe Subarachnoid Hemorrhage (WFNS 1-2) Using Speckle-tracking Echocardiography (STRAIN)

Actual Study Start Date :

Jan 2, 2019

Actual Primary Completion Date :

Dec 25, 2020

Actual Study Completion Date :

Jan 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Patients with a "non-severe" subarachnoid hemorrhage	Diagnostic Test: Global Longitudinal Strain measure Global Longitudinal Strain measure on day 1 of hospitalization

Arm

Intervention/Treatment

Patients with a "non-severe" subarachnoid hemorrhage

Diagnostic Test: Global Longitudinal Strain measure

Global Longitudinal Strain measure on day 1 of hospitalization

Outcome Measures

Primary Outcome Measures

Global Longitudinal Strain [Day 1 of hospitalization]
It is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.

Secondary Outcome Measures

Global Longitudinal Strain [Day 3 of hospitalization]
is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.
Global Longitudinal Strain [Day 7 of hospitalization]
is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.
Change of Left Ventricular Ejection Fraction using Simpson technique [Days 1, 3 and 7 of hospitalization]
Change in serum troponin level [Days 1, 3 and 7 of hospitalization]
Change in brain natriuretic peptide (BNP) level [Days 1, 3 and 7 of hospitalization]
Electrocardiogram abnormalities [Up to day 7 of hospitalization]
Abnormalities expected: abnormal Q or QS wave (≥30 ms or a pathological R wave in V1 to V2) ST de- pression (ST depression ≥ 0.1 mV, 80 ms post-J point) ST elevation (ST elevation ≥ .1 mV) peaked upright T wave (prominent peaked T wave) T-wave inver- sion (pathologic T-wave inversion) nonspecific ST- or T-wave changes